About
Genetic Neuroscience Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (15)
View allTotal Trials
15
As Lead Sponsor
15
As Collaborator
0
Total Enrollment
2,165
By Phase
PHASE3: 3PHASE1: 1PHASE2: 6PHASE2/PHASE3: 3PHASE1/PHASE2: 1
By Status
RECRUITING: 6COMPLETED: 5NOT_YET_RECRUITING: 1ENROLLING_BY_INVITATION: 1WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07019922Lead Sponsor
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
PHASE3Recruiting
50 participants
Started: Aug 13, 2025 · Completed: Dec 31, 2028
NCT07010471Lead Sponsor
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
PHASE3Recruiting
160 participants
Started: Jul 9, 2025 · Completed: Jul 31, 2027
NCT06840925Lead Sponsor
A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628
PHASE1Not yet recruiting
16 participants
Started: Mar 24, 2025 · Completed: Jun 30, 2025
NCT06908356Lead Sponsor
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
PHASE2Recruiting
50 participants
Started: Jan 10, 2025 · Completed: Jul 31, 2025
NCT06999902Lead Sponsor
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
PHASE2/PHASE3Recruiting
230 participants
Started: Dec 11, 2024 · Completed: Dec 8, 2025
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...